<DOC>
	<DOCNO>NCT00264199</DOCNO>
	<brief_summary>The purpose study determine whether 48 hour glucagon-like-peptide-1 ( GLP-1 ) infusion improve heart function alter substrate metabolism non-diabetic patient heart failure .</brief_summary>
	<brief_title>Effect 48 Hours Treatment With Natural Peptide-Hormone GLP-1 Patients With Chronic Heart Failure</brief_title>
	<detailed_description>Heart failure major complication patient ischemic heart disease . It show many patient area viable myocardium effectively contribute heart function . Further , chronic congestive heart failure associate degree insulin resistance skeletal cardiac muscle . GLP-1 naturally occur peptide hormone act incretin intensively study many group association type II diabetes clearly show glucose lower potential little risk hypoglycemia several trial . Recently GLP-1 show improve cardiac function dog pace-induced cardiomyopathy , open-labeled study improve cardiac function patient acute myocardial infarction . Comparison : 48 hour treatment intravenous GLP-1 compare placebo . Effect global regional leave ventricular function , exercise capacity , insulin sensitivity substrate metabolism .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Chronic congestive heart failure Ischemic heart disease Diabetes Exercise limit disease heart failure Congenital heart disease Arteriovenous shunt Renal failure Valvular heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Chronic Congestive heart failure</keyword>
	<keyword>Ischemic heart disease</keyword>
	<keyword>insulin resistance</keyword>
</DOC>